Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dicerna and PBL Sign Agreement for Baulcombe & Hamilton RNAi Patents

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Dicerna Pharmaceuticals, Inc. (Dicerna) and Plant Bioscience Limited (PBL), announced that they have entered an agreement for a non-exclusive licence to PBL’s RNAi intellectual property estate.

PBL will grant Dicerna a world-wide, non-exclusive license to the Baulcombe patents (U.S. Patent Nos. 8,097,710; 8,258,285; 8,299,235 and 8,263,569) for use in the field of human therapeutics.  Financial terms were not disclosed.

“We are pleased to add the Baulcombe patents to our expanding intellectual property portfolio,” said Douglas M. Fambrough, CEO of Dicerna.  “We have continued to innovate and advance our DsiRNA and EnCore technologies, allowing us to develop innovative programs against previously undruggable targets.  Dicerna’s programs, along with those of our partners, means we are moving forward on multiple fronts to bring new options to patients via well-known and powerful mechanisms.”

PBL’s Managing Director, Dr. Jan Chojecki, stated, “We are delighted to add Dicerna as our partner in the development of RNAi therapeutics. Dicerna is currently advancing an exciting RNAi-based therapeutic oncology candidate into the development stage.  This agreement further endorses the strength of our patent estate in the RNAi field and we look forward to working with other partners in therapeutic applications, as well as in research reagents, diagnostics and of course agricultural applications of this pivotal technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dicerna Reports Progress with GalNAc-DsiRNA-EX-Conjugates
Dicerna has presented preclinical data suggesting the feasibility of its proprietary GalNAc-DsiRNA-EX-Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) or intravenous (IV) injection.
Thursday, March 03, 2016
Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates
The company, a leader in the development of RNA interference (RNAi) therapeutics, presented preclinical data demonstrating the feasibility of its proprietary DsiRNA-EX Conjugate-mediated delivery technology.
Thursday, May 07, 2015
Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer
Mr. Weissman joins Dicerna with more than 25 years in the life sciences industry and will be responsible for corporate development, strategy and other operational functions.
Thursday, January 05, 2012
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!